BioEcho develops single-spin and 96/384-well kits based on the patent pending single-step EchoLUTION nucleic acid extraction process. Highly superior to the commonly used silica-based solutions (bind-wash-elute), the isolated inhibitor-free RNA/DNA is detected with increased sensitivity. Furthermore, the whole procedure is up to 20-fold faster: Washing steps are not required, saving time, costs and plastic waste. Due to the expertise of its founders and employees, BioEcho also uses its know-how to support diagnostic or pharma companies with specialized scientific knowledge. Especially in times like these, BioEcho helps to accelerate accurate tests on certain RNA/DNA viruses such as SARS-CoV-2.
Redx appoints new CMO
AppointmentsIn March 2021, Dr Jane Robertson will take over the position of Chief Medical Officer at Redx Pharma Plc in Alderley Park.
BI initiates Phase II testing of COVID-19 drug
Latest NewsBoehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in patients hospitalised for COVID-19.
AP-Protector® – Diluent for long-term storage of AP conjugates
ProductsAP-Protector® is a long-term stabilizer for alkaline phosphatase (AP) coupled to antibodies or Neutravidin/Streptavidin.
3P Bio to manufacture SpyBiotech vaccine
Latest NewsBritish SpyBiotech has outsourced GMP manufacturing of its VLP vaccine platform to Navarra-based 3P Biopharmaceuticals.
Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
Latest NewsSwedish BioInvent AB has licensed its anti-Fc?RllB antibody BI-1206 for $95m to CASI Pharmaceuticals for distribtion in the Greater China region
Transgene reports clinical results of TG4001 plus avelumab
Latest NewsTransgene SA has reported positive results of an exploratory Phase Ib/II study in HPV-16-positive cancers combining its cancer vaccine TG4001 with Merck KgaA’s PD-L1 blocker avelumab.
“The COVID-19 impact was not all bad”
OpinionMedical Cannabis – Last year, the European Cannabis Association was launched as industry interest group, but than the novel coronavirus pandemic changed everything. European Biotechnology spoke with Rainer Krüger, one of the ECA founders, how the virus changed the schedule and strategy to establish a science-based regulation for medicinal cannabis.
Roche licences antiviral nucleoside from Atea
Latest NewsRoche AG has paid US$350 in cash to co.develop and market Atea Pharmaceutical’s oral direct-acting antiviral, AT-527, to limit proliferation of SARS-CoV-2.
ADC company Araris Biotech raises CHF15.2m
Latest NewsNew ADC company Araris Biotech has got backing by Pureos Bioventures and co-investors in a CHF15.2m seed round to develop a new class of antibody drug conjugates.
·
The ultra-fast track to viral RNA and genomic DNA
Sponsored PublicationsBioEcho develops single-spin and 96/384-well kits based on the patent pending single-step EchoLUTION nucleic acid extraction process. Highly superior to the commonly used silica-based solutions (bind-wash-elute), the isolated inhibitor-free RNA/DNA is detected with increased sensitivity. Furthermore, the whole procedure is up to 20-fold faster: Washing steps are not required, saving time, costs and plastic waste. Due to the expertise of its founders and employees, BioEcho also uses its know-how to support diagnostic or pharma companies with specialized scientific knowledge. Especially in times like these, BioEcho helps to accelerate accurate tests on certain RNA/DNA viruses such as SARS-CoV-2.